Tafamidis, also known by its brand names Vyndamax and Vyndaqel, is a medication approved by the U.S. Food and Drug Administration (FDA) to treat people with hereditary (hATTR) and wild-type amyloidosis, particularly those with heart symptoms. Studies have shown that tafamidis can improve neurological function, delay disease Show Full Answer

Tafamidis, also known by its brand names Vyndamax and Vyndaqel, is a medication approved by the U.S. Food and Drug Administration (FDA) to treat people with hereditary (hATTR) and wild-type amyloidosis, particularly those with heart symptoms. Studies have shown that tafamidis can improve neurological function, delay disease progression, and enhance quality of life. It is generally considered safe, with some participants experiencing serious adverse events like chest pain and urinary tract infections, but no deaths were associated with the treatment.

If you are in England and considering or have started on tafamidis, it would be beneficial to discuss your experiences with your healthcare provider and support groups to share insights and gather more information.

 This AI-generated response comes from MyAmyloidosisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

hATTR Amyloidosis Treatments: Comparing Your Options | MyAmyloidosisTeam

Vyndaqel (Tafamidis meglumine) for Amyloidosis | MyAmyloidosisTeam